EquityFlow
›
Companies
› AMLo Biosciences
AMLo Biosciences
Biotech
· Newcastle, GB ·
amlobiosciences.com
Early-stage skin cancer prognostic test developer
Funding history
Date
Round
Amount
Apr 2022
Seed
AMLo Biosciences, a Newcastle University spinout developing a skin cancer test, raised GBP2.45M from Future Planet Capital, Ascension and NorthStar Ventures.
$3.1M
Investors
Ascension
Future Planet Capital
NorthStar Ventures
Similar companies in Biotech
Imperagen
Haga Bioscience
Pixelgen Technologies
Gallant
Chai Discovery
SNIPR Biome
Cellbox Labs
Scope Biosciences
GenLumina
Actithera
NUCLIDIUM
Anocca
Explore funding flow on EquityFlow →